NO940597L - Isolering, vekst, differensiering og genslöyd på menneskers muskelceller - Google Patents

Isolering, vekst, differensiering og genslöyd på menneskers muskelceller

Info

Publication number
NO940597L
NO940597L NO940597A NO940597A NO940597L NO 940597 L NO940597 L NO 940597L NO 940597 A NO940597 A NO 940597A NO 940597 A NO940597 A NO 940597A NO 940597 L NO940597 L NO 940597L
Authority
NO
Norway
Prior art keywords
differentiation
isolation
growth
muscle cells
gene silencing
Prior art date
Application number
NO940597A
Other languages
English (en)
Other versions
NO940597D0 (no
Inventor
Helen M Blau
Simon M Hughes
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Publication of NO940597D0 publication Critical patent/NO940597D0/no
Publication of NO940597L publication Critical patent/NO940597L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0658—Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/33—Insulin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Det fremstilles myoblaster, hensiktsmessig i lavt eller serum-fritt medium, for anvendelse til innføring i en pattedyrvert, særlig en menneskevert, for behandling av sykdommer i muskelvev eller for å virke som bærere for genetiske evner, særlig for korrigering av en genetisk defekt eller for fremstilling av et løselig protein som kan anvendes i terapi for pattedyrverten. Myoblaster som innføres i vev, er i stand til å migrere til steder langt fra injeksjonsstedet, hvilket utvider deres virkningsområde.
NO940597A 1991-08-22 1994-02-21 Isolering, vekst, differensiering og genslöyd på menneskers muskelceller NO940597L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/748,348 US5538722A (en) 1989-06-13 1991-08-22 Isolation, growth, differentiation and genetic engineering of human muscle cells
PCT/US1992/006983 WO1993003768A1 (en) 1991-08-22 1992-08-19 Isolation, growth, differentiation and genetic engineering of human muscle cells

Publications (2)

Publication Number Publication Date
NO940597D0 NO940597D0 (no) 1994-02-21
NO940597L true NO940597L (no) 1994-04-19

Family

ID=25009080

Family Applications (1)

Application Number Title Priority Date Filing Date
NO940597A NO940597L (no) 1991-08-22 1994-02-21 Isolering, vekst, differensiering og genslöyd på menneskers muskelceller

Country Status (8)

Country Link
US (1) US5538722A (no)
EP (1) EP0667791A4 (no)
JP (1) JPH07501688A (no)
KR (1) KR100275304B1 (no)
AU (1) AU659673B2 (no)
CA (1) CA2116118A1 (no)
NO (1) NO940597L (no)
WO (1) WO1993003768A1 (no)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5298422A (en) * 1991-11-06 1994-03-29 Baylor College Of Medicine Myogenic vector systems
US5661133B1 (en) * 1991-11-12 1999-06-01 Univ Michigan Collateral blood vessel formation in cardiac muscle by injecting a dna sequence encoding an angiogenic protein
JPH07509217A (ja) * 1992-03-04 1995-10-12 ウォルフ　ジョン　エイ 治療物質を脳に送出する方法
US6432711B1 (en) * 1993-11-03 2002-08-13 Diacrin, Inc. Embryonic stem cells capable of differentiating into desired cell lines
WO1995013376A1 (en) * 1993-11-10 1995-05-18 Amgen Inc. Gene therapy vector for the treatment of low or defective red blood cell production
US5840576A (en) 1994-07-20 1998-11-24 Cytotherapeutics, Inc. Methods and compositions of growth control for cells encapsulated within bioartificial organs
US5935849A (en) 1994-07-20 1999-08-10 Cytotherapeutics, Inc. Methods and compositions of growth control for cells encapsulated within bioartificial organs
GB9419048D0 (en) * 1994-09-20 1994-11-09 Watt Diana J Treatment of muscular disorders
US6495364B2 (en) * 1995-05-23 2002-12-17 Neurotech, S.A. Mx-1 conditionally immortalized cells
US5869041A (en) 1996-01-12 1999-02-09 The Miriam Hospital Delivery of bioactive compounds to an organism
FR2746109B1 (fr) 1996-03-12 1998-04-17 Rhone Poulenc Rorer Sa Milieu pour la conservation de materiel biologique
US6281371B1 (en) 1997-08-13 2001-08-28 Biontex Laboratories Gmbh Lipopolyamines, and the preparation and use thereof
US6866842B1 (en) 1998-05-01 2005-03-15 University Of Pittsburgh Muscle-derived cells (MDCs) for treating muscle-or bone-related injury or dysfunction
US7115417B1 (en) * 1998-05-01 2006-10-03 Chancellor Michael B Soft tissue and bone augmentation and bulking utilizing muscle-derived progenito compositions, and treatments thereof
WO1999056785A2 (en) 1998-05-01 1999-11-11 University Of Pittsburgh Cell mediated gene delivery using muscle derived cells for treating muscle-and bone-related injury or dysfunction
ATE299178T1 (de) * 1999-04-27 2005-07-15 Transgene Sa Verfahren zur herstellung von säugetier-zellinien
EP1048724A1 (en) * 1999-04-27 2000-11-02 Transgene S.A. Human myoblast cell lines and their uses
AU5498800A (en) * 1999-06-25 2001-01-31 Baylor College Of Medicine Stem cells derived from skeletal muscle
US20030113301A1 (en) * 1999-07-23 2003-06-19 Albert Edge Muscle cells and their use in cardiac repair
CA2378643A1 (en) 1999-07-23 2001-02-01 Diacrin, Inc. Muscle cells and their use in cardiac repair
ES2288946T3 (es) * 2000-04-14 2008-02-01 University Of Pittsburgh Aumento y abultamiento de tejido blando y hueso utilizando celulas progenitoras derivadas de musculo, sus composiciones y tratamientos.
DE10026480A1 (de) * 2000-05-29 2001-12-13 Augustinus Bader Verfahren zur Herstellung eines empfängerspezifischen Gewebe-Transplantats oder -Implantats
FR2810045B1 (fr) * 2000-06-07 2004-09-03 Assist Publ Hopitaux De Paris Procede d'obtention de population cellulaires caracterisees d'origine musculaire et utilisations
WO2002066076A1 (en) * 2001-02-21 2002-08-29 Melbourne Neuromuscular Research Institute A method of treatment and agents useful for same
JP4680483B2 (ja) * 2001-02-23 2011-05-11 ユニバーシティ オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 組織および臓器の治療および修復に用いるための幹細胞マトリックスの迅速な調製方法
EP1497410A4 (en) * 2002-04-01 2005-05-25 Peter K Law CELL TRANSPLANTATION FOR CARDIAC REGENERATION
US20040009155A1 (en) * 2002-07-12 2004-01-15 Maria Palasis Method for sustaining direct cell delivery
US20040191225A1 (en) * 2002-08-06 2004-09-30 Dinsmore Jonathan H. Injection system
US7627373B2 (en) 2002-11-30 2009-12-01 Cardiac Pacemakers, Inc. Method and apparatus for cell and electrical therapy of living tissue
ATE482713T1 (de) 2003-04-25 2010-10-15 Univ Pittsburgh Von muskeln stammende zellen (mdcs) zur förderung und verbesserung der nervenreparatur und - regeneration
US7840263B2 (en) * 2004-02-27 2010-11-23 Cardiac Pacemakers, Inc. Method and apparatus for device controlled gene expression
US7764995B2 (en) 2004-06-07 2010-07-27 Cardiac Pacemakers, Inc. Method and apparatus to modulate cellular regeneration post myocardial infarct
US7828711B2 (en) * 2004-08-16 2010-11-09 Cardiac Pacemakers, Inc. Method and apparatus for modulating cellular growth and regeneration using ventricular assist device
US7981065B2 (en) 2004-12-20 2011-07-19 Cardiac Pacemakers, Inc. Lead electrode incorporating extracellular matrix
US8060219B2 (en) 2004-12-20 2011-11-15 Cardiac Pacemakers, Inc. Epicardial patch including isolated extracellular matrix with pacing electrodes
US20060263338A1 (en) * 2005-03-04 2006-11-23 Jacoby Douglas B Catheter-based delivery of Skeletal Myoblasts to the Myocardium of Damaged Hearts
WO2006121532A2 (en) * 2005-03-31 2006-11-16 Mytogen, Inc. Treatment for heart disease
WO2006122005A2 (en) * 2005-05-09 2006-11-16 Mytogen, Inc. Cellular cardiomyoplasty as supportive therapy in patients with heart disease
EP2097088B2 (en) * 2006-11-28 2024-06-12 University of Pittsburgh - of the Commonwealth System of Higher Education Muscle derived cells for the treatment of cardiac pathologies and methods of making and using the same
US20100158875A1 (en) 2006-12-18 2010-06-24 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Muscle derived cells for the treatment of gastro-esophageal pathologies and methods of making and using the same
WO2008076435A1 (en) * 2006-12-18 2008-06-26 University Of Pittsburgh Muscle derived cells for the treatment of gastro-esophageal pathologies and methods of making and using the same
DK2118271T3 (en) 2007-01-11 2018-07-23 Univ Pittsburgh Commonwealth Sys Higher Education MUSCLE DERIVATIVE CELLS FOR THE TREATMENT OF URINARY DISEASES AND PROCEDURES FOR THEIR PREPARATION AND USE
US20080208164A1 (en) * 2007-02-28 2008-08-28 Innovacell Biotechnologie Gmbh Methods for the treatment of anal incontinence
JP5624461B2 (ja) * 2007-05-29 2014-11-12 ユニバーシティー オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション 筋肉由来前駆体組成物を利用する骨の増大およびその処理
US20080311219A1 (en) * 2007-06-15 2008-12-18 Anna Gosiewska Tissue Fragment Compositions for the Treatment of Incontinence
AU2008307519B9 (en) 2007-10-04 2014-11-13 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Skeletal muscle augmentation utilizing muscle-derived progenitor compositions, and treatments thereof
EP2328596B1 (en) * 2008-08-18 2019-03-06 University of Pittsburgh - Of the Commonwealth System of Higher Education Bone augmentation utilizing muscle-derived progenitor compositions in biocompatible matrix, and treatments thereof
US20100233138A1 (en) * 2008-11-07 2010-09-16 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Vocal Cord Augmentation Utilizing Muscle-Derived Progenitor Compositions, and Treatments Thereof
FR2960783B1 (fr) 2010-06-04 2012-07-27 Ass Pour Les Transferts De Technologies Du Mans Membrane fonctionnalisee pour chambre d'encapsulation de cellules produisant au moins une substance d'interet therapeutique et organe bioartificiel comprenant une telle membrane
US9295696B2 (en) 2012-06-08 2016-03-29 University of Pittsburgh—of the Commonwealth System of Higher Education Compositions and methods for restoring or rejuvenating stem/progenitor cell function
EP2898089A1 (en) 2012-09-24 2015-07-29 Innovacell Biotechnologie AG Potency assay for skeletal muscle derived cells
EP3095509A1 (en) 2015-05-18 2016-11-23 Defymed Membranes functionalized with heparin for bioartificial organs
JP6890553B2 (ja) 2015-06-11 2021-06-18 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティ オブ イリノイＴｈｅ Ｂｏａｒｄ Ｏｆ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｉｌｌｉｎｏｉｓ 筋ジストロフィーキメラ細胞および筋ジストロフィーの処置方法
CN111406106A (zh) 2017-11-28 2020-07-10 伊利诺伊大学理事会 多嵌合细胞以及移植疗法与免疫缺陷和遗传病症的治疗
US11617768B2 (en) 2017-12-14 2023-04-04 Innovacell Ag Methods for obtaining muscle derived cells
WO2020238961A1 (en) * 2019-05-29 2020-12-03 Institute Of Zoology, Chinese Academy Of Sciences Compositions and use of engineered myogenic cells

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4443546A (en) * 1980-07-07 1984-04-17 The Beth Israel Hospital Association Process and composition for propagating mammalian cells
US4520821A (en) * 1982-04-30 1985-06-04 The Regents Of The University Of California Growing of long-term biological tissue correction structures in vivo
ES2116269T3 (es) * 1989-03-21 1998-07-16 Vical Inc Expresion de secuencias exogenas de polinucleotidos en un vertebrado.
WO1990015863A1 (en) * 1989-06-13 1990-12-27 The Board Of Directors Of The Leland Stanford Junior University Isolation growth and differentiation of human muscle cells
AU633958B2 (en) * 1989-07-25 1993-02-11 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
AU7312891A (en) * 1990-02-12 1991-09-03 Board Of Regents, The University Of Texas System Satellite cell proliferation in adult skeletal muscle
FR2681786A1 (fr) * 1991-09-27 1993-04-02 Centre Nat Rech Scient Vecteurs recombinants d'origine virale, leur procede d'obtention et leur utilisation pour l'expression de polypeptides dans des cellules musculaires.
NZ245015A (en) * 1991-11-05 1995-12-21 Transkaryotic Therapies Inc Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production
WO1993014778A1 (en) * 1992-01-23 1993-08-05 Vical, Inc. Ex vivo gene transfer
US5681735A (en) * 1992-04-10 1997-10-28 Fox Chase Cancer Center Transcription control element for increasing gene expression in myoblasts
AU4385393A (en) * 1992-05-29 1993-12-30 General Hospital Corporation, The Arterial introduction of myoblasts

Also Published As

Publication number Publication date
JPH07501688A (ja) 1995-02-23
EP0667791A4 (en) 1996-05-08
NO940597D0 (no) 1994-02-21
AU2515792A (en) 1993-03-16
KR100275304B1 (ko) 2000-12-15
CA2116118A1 (en) 1993-03-04
AU659673B2 (en) 1995-05-25
EP0667791A1 (en) 1995-08-23
US5538722A (en) 1996-07-23
WO1993003768A1 (en) 1993-03-04

Similar Documents

Publication Publication Date Title
NO940597L (no) Isolering, vekst, differensiering og genslöyd på menneskers muskelceller
Silverman et al. Angiogenic activity of adipose tissue
Eccles et al. Immunologically-mediated restraint of latent tumour metastases
Morykwas et al. Vacuum-assisted closure: a new method for wound control and treatment: animal studies and basic foundation
Ronfard et al. Use of human keratinocytes cultured on fibrin glue in the treatment of burn wounds
ATE153856T1 (de) Zusammensetzung zur stimulierung des immunsystems
NO890587L (no) Nye proteiner med faktor viii aktivitet: fremgangsmaate for fremstilling derav ved anvendelse av genetisk omkonstruerte celler og farmasoeytiske sammensetninger som inneholderdisse.
EP0400958A3 (en) Live vaccines
DK509286A (da) Neovaskulariseringsinhibitor og fremgangsmaade til fremstilling derafsamt anvendelse deraf
US4197291A (en) Hydrolytic enzyme material
DE69635924D1 (de) Isolierung und züchtung von schwannzellen
Fukuda et al. Type V collagen selectively inhibits human endothelial cell proliferation
NO924323L (no) Nye hybridtransformerende vekstfaktorer
RU98107327A (ru) Нейротрансплантация с использованием плюрипотентных нейроэпителиальных клеток
BR0312365A (pt) Meio de cultura autólogo de células-mães progenitoras autólogas humanas, métodos para a preparação do mesmo e de uma composição de células-mães progenitoras autólogas humanas e para a obtenção de células-mães progenitoras musculares autólogas humanas, emprego de um meio de cultura autólogo de células-mães progenitoras autólogas humanas, procedimento para a obtenção de células-mães progenitoras musculares autólogas humanas e procedimento terapêutico de cardiomioplastia celular autóloga, composição enriquecida com células-mães progenitoras musculares autólogas humanas e composição farmacêutica
CA2368677A1 (en) Intramyocardial injection of autologous bone marrow
JPH03503167A (ja) 部位指定血管形成素子とその使用法
KANTOR et al. The difference in permeability of cartilage to cationic and anionic dyes
Taylor et al. Studies on a serum substitute for mammalian cells in culture I. Biological efficacy of whole and fractionated peptone dialysate
ATE267843T1 (de) Verfahren zur herstellung von selbstvernetzten hyaluronsäuren und deren derivaten mittels superkritischer anti-lösungsmittel
AU4819999A (en) A method for inducing production of growth factors
SE8104458L (sv) Vattenloslig fraktion med formaga att reglera immunreaktioner hos ett verddjur gentemot allogena celler eller vevnad, farmaceutiska kompositioner, innehallande nemnda fraktion, samt sett att framstella sistnemnda
Basile Inhibition of proline-hydroxyproline metabolism and phenovariation of Scapania nemorosa
HEBDA et al. Support and stimulation of epidermal cell outgrowth from porcine skin explants by platelet factors
CN104906634A (zh) 一种人3d结构表皮细胞膜片的制备方法及其临床应用

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application